# CSL Behring clinical trials: 145 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 145 trials with CSL Behring as lead sponsor, 15 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by CSL Behring: 145 rows for $7.25, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/csl-behring

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 145
- Recruiting or not yet: 15
- Read on: November 19, 2026

## Trials

The 25 newest of 145, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| June 15, 2026 | NCT07648264 | Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting... | CSL Behring | Phase 3 | Recruiting | Secondary Immune Deficiency | 63 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07648264) |
| June 2, 2026 | NCT07619820 | A Phase 1b Study to Evaluate the PK of CSL300 (Clazakizumab) in Chinese Subjects With End Stage Kidney Disease (ESKD) | CSL Behring | Phase 1 | Recruiting | End Stage Kidney Disease (ESKD) | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07619820) |
| January 12, 2026 | NCT07332091 | Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis | CSL Behring | Phase 2 | Active not recruiting | Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07332091) |
| January 8, 2026 | NCT07326592 | Phase 4, Double-blind Study Evaluating the Response on Computed Tomography (CT) Lung Density Decline Rates of Respreeza / Zemaira Weekly... | CSL Behring | Phase 4 | Recruiting | Alpha1 Antitrypsin Deficiency, Alpha1-Proteinase Inhibitor Deficiency, Emphysema | 270 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07326592) |
| November 4, 2025 | NCT07224360 | Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD) | CSL Behring | Phase 2 | Recruiting | Sickle Cell Disease | 63 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07224360) |
| September 8, 2025 | NCT07159464 | Post Study Access of CSL312 (Garadacimab) for Pediatric Participants With Hereditary Angioedema Who Have Completed the CSL312\_3003 Study | CSL Behring | Not applicable | Available | Hereditary Angioedema (HAE) | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07159464) |
| July 30, 2025 | NCT07094087 | Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovascular Surgery With... | CSL Behring | Phase 3 | Recruiting | Complex Cardiovascular Surgery With Cardiopulmonary Bypass | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07094087) |
| July 23, 2025 | NCT07080905 | Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to \< 18 Years of Age) With Severe or Moderately Severe... | CSL Behring | Phase 3 | Recruiting | Hemophilia B | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07080905) |
| July 22, 2025 | NCT07076446 | An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin... | CSL Behring | Phase 4 | Completed | Primary Immunodeficiency | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07076446) |
| July 2, 2025 | NCT07048262 | Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB) | CSL Behring | Phase 2 | Recruiting | Non-cystic Fibrosis Bronchiectasis | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07048262) |
| June 3, 2025 | NCT07001280 | A Study Investigating the Effectiveness and Safety of Garadacimab for Treating Patients With Hereditary Angioedema (HAE) | CSL Behring | Observational | Recruiting | Hereditary Angioedemas | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07001280) |
| May 30, 2025 | NCT06996184 | Effect of Food on the Oral Bioavailability of a Prolonged-release Formulation of Vamifeport in Healthy Adults | CSL Behring | Phase 1 | Completed | Healthy Volunteers | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06996184) |
| February 4, 2025 | NCT06806657 | Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab | CSL Behring | Phase 4 | Completed | Hereditary Angioedema | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06806657) |
| December 17, 2024 | NCT06738485 | Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII Products | CSL Behring | Phase 3 | Completed | Congenital Hemophilia A | 62 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06738485) |
| December 10, 2024 | NCT06726863 | Pharmacokinetics and Pharmacodynamics of Two Prolonged-release Formulations of Vamifeport in Healthy Adults | CSL Behring | Phase 1 | Completed | Healthy Volunteers | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06726863) |
| November 21, 2024 | NCT06699849 | Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis | CSL Behring | Phase 2 | Recruiting | Sickle Cell Disease Vaso-occlusive Crisis | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06699849) |
| October 1, 2024 | NCT06617897 | Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery | CSL Behring | Phase 3 | Recruiting | Acquired Fibrinogen Deficiency | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06617897) |
| July 29, 2024 | NCT06524739 | Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS | CSL Behring | Phase 3 | Terminated | Post-COVID Postural Orthostatic Tachycardia Syndrome | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06524739) |
| May 3, 2024 | NCT06399289 | Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Chinese Subjects With Hemophilia B Previously Treated... | CSL Behring | Phase 3 | Completed | Hemophilia B | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06399289) |
| August 24, 2023 | NCT06008938 | An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B | CSL Behring | Observational | Recruiting | Hemophilia B | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06008938) |
| August 22, 2023 | NCT06003387 | Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus... | CSL Behring | Phase 3 | Recruiting | Hemophilia B | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06003387) |
| July 27, 2023 | NCT05962398 | Long-term Follow-up Study of Male Adults With Hemophilia B Previously Treated With Etranacogene Dezaparvovec (CSL222) | CSL Behring | Observational | Enrolling by invitation | Hemophilia B | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05962398) |
| July 10, 2023 | NCT05937581 | First-In-Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Escalating Single And Multiple Doses... | CSL Behring | Phase 1 | Completed | Complement-mediated Disorders | 62 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05937581) |
| April 19, 2023 | NCT05819775 | CSL312\_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema | CSL Behring | Phase 3 | Completed | Hereditary Angioedema (HAE) | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05819775) |
| December 16, 2022 | NCT05653713 | Effects of CSL324 in the Lung After Segmental Challenge | CSL Behring | Phase 1 | Completed | Healthy Volunteers | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05653713) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 22 |
| Phase 1/2 | 5 |
| Phase 2 | 26 |
| Phase 2/3 | 7 |
| Phase 3 | 51 |
| Phase 4 | 13 |
| Not applicable | 1 |
| Observational | 20 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 106 |
| Terminated | 16 |
| Recruiting | 15 |
| Withdrawn | 4 |
| Active not recruiting | 2 |
| Available | 1 |
| Enrolling by invitation | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Hemophilia B | 17 |
| Hemophilia A | 13 |
| Angioedemas, Hereditary | 11 |
| Primary Immunodeficiency Diseases | 11 |
| von Willebrand Diseases | 7 |
| Hereditary Angioedema Types I and II | 5 |
| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 5 |
| Agammaglobulinemia | 5 |
| Common Variable Immunodeficiency | 5 |
| Anemia, Sickle Cell | 4 |
| alpha 1-Antitrypsin Deficiency | 4 |
| Hemorrhage | 3 |
| Hemostatic Disorders | 3 |
| IgG Deficiency | 3 |
| Emphysema | 3 |
| Arthritis, Rheumatoid | 3 |
| Blood Coagulation Disorders | 3 |
| Factor XIII Deficiency | 3 |
| COVID-19 | 3 |
| Atherosclerosis | 3 |
| Afibrinogenemia | 3 |
| Purpura, Thrombocytopenic, Idiopathic | 2 |
| Blood Loss, Surgical | 2 |
| Scleroderma, Diffuse | 2 |
| Iron Overload | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Security companies in the United States](https://specstream.ai/data/businesses/security-companies/united-states)
- [Eastern European restaurants in the United States](https://specstream.ai/data/businesses/eastern-european-restaurants/united-states)
- [Rheumatology practices in the United States](https://specstream.ai/data/businesses/rheumatology-practices/united-states)
- [Distribution companies in the United States](https://specstream.ai/data/businesses/distribution-companies/united-states)
- [Rail services in the United States](https://specstream.ai/data/businesses/rail-services/united-states)
- [Damage restoration companies in the United States](https://specstream.ai/data/businesses/damage-restoration-companies/united-states)
